RAW SEQUENCE LISTING
PATENT APPLICATION: **US/10/050,190**

DATE: 10/06/2004
TIME: 15:48:33

Input Set : **N:\Crf3\RULE60\10050190.raw**
Output Set: **N:\CRF4\10062004\J050190.raw**

```
 1 <110> APPLICANT: STEM CELL PHARMACEUTICALS, INC.
 2       TWARDZIK, Daniel R.
 3       PERNET, Andre
 4       FELKER, Thomas S.
 5       PASKELL, Stefan
 6 <120> TITLE OF INVENTION: TGF-alpha POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND
 7       METHODS OF USE THEREFOR
 8 <130> FILE REFERENCE: STEM1110-2
 9 <140> CURRENT APPLICATION NUMBER: 10/050,190
10 <141> CURRENT FILING DATE: 2002-01-15
11 <150> PRIOR APPLICATION NUMBER: US/09/641,587
12 <151> PRIOR FILING DATE: 2000-08-17
13 <150> PRIOR APPLICATION NUMBER: US 09/559,248
14 <151> PRIOR FILING DATE: 2000-04-26
15 <150> PRIOR APPLICATION NUMBER: US 09/459,813
16 <151> PRIOR FILING DATE: 1999-12-13
17 <150> PRIOR APPLICATION NUMBER: US 09/492,935
18 <151> PRIOR FILING DATE: 2000-01-27
19 <150> PRIOR APPLICATION NUMBER: US 09/378,567
20 <151> PRIOR FILING DATE: 1999-08-19
21 <160> NUMBER OF SEQ ID NOS: 7
22 <170> SOFTWARE: PatentIn version 3.1
24 <210> SEQ ID NO: 1
25 <211> LENGTH: 50
26 <212> TYPE: PRT
27 <213> ORGANISM: Homo sapiens
28 <400> SEQUENCE: 1
29       Val Val Ser His Phe Asn Asp Cys Pro Asp Ser His Thr Gln Phe Cys
30       1               5                   10                  15
31       Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Asp Lys Pro Ala Cys
32                   20                  25                  30
33       Val Cys His Ser Gly Tyr Val Gly Ala Arg Cys Glu His Ala Asp Leu
34               35                  40                  45
35       Leu Ala
36           50
38 <210> SEQ ID NO: 2
39 <211> LENGTH: 50
40 <212> TYPE: PRT
41 <213> ORGANISM: Rattus norvegicus
42 <400> SEQUENCE: 2
43       Val Val Ser His Phe Asn Lys Cys Pro Asp Ser His Thr Gln Tyr Cys
44       1               5                   10                  15
45       Phe His Gly Thr Cys Arg Phe Leu Val Gln Glu Glu Lys Pro Ala Cys
```

```
                    RAW SEQUENCE LISTING           DATE: 10/06/2004
                    PATENT APPLICATION:  US/10/050,190    TIME: 15:48:33

                    Input Set  : N:\Crf3\RULE60\10050190.raw
                    Output Set: N:\CRF4\10062004\J050190.raw
```

```
46                      20                25                30
47         Val Cys His Ser Gly Tyr Val Gly Val Arg Cys Glu His Ala Asp Leu
48              35                40                45
49         Asp Ala
50              50
52 <210> SEQ ID NO: 3
53 <211> LENGTH: 57
54 <212> TYPE: PRT
55 <213> ORGANISM: Artificial Sequence
56 <220> FEATURE:
57 <223> OTHER INFORMATION: A modified human TGF-alpha sequence
58 <400> SEQUENCE: 3
59         Ser Leu Ser Leu Pro Ala Met Val Val Ser His Phe Asn Asp Cys Pro
60         1              5                10                15
61         Asp Ser His Thr Gln Phe Cys Phe His Gly Thr Cys Arg Phe Leu Val
62                      20                25                30
63         Gln Glu Asp Lys Pro Ala Cys Val Cys His Ser Gly Tyr Val Gly Ala
64              35                40                45
65         Arg Cys Glu His Ala Asp Leu Leu Ala
66              50                55
68 <210> SEQ ID NO: 4
69 <211> LENGTH: 11
70 <212> TYPE: PRT
71 <213> ORGANISM: Artificial Sequence
72 <220> FEATURE:
73 <223> OTHER INFORMATION: Modified human TGF alpha sequence fragment
74 <220> FEATURE:
75 <221> NAME/KEY: MISC_FEATURE
76 <222> LOCATION: (1)..(10)
77 <223> OTHER INFORMATION: Xaa at residue 1, 5, 7 to 9 is independently V, G or A;
78 <223> OTHER INFORMATION: Xaa at residue 6 is Y or F; and Xaa at residue 10 is R or K
W--> 79 <400> 4
W--> 80         Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys
81         1              5                10
83 <210> SEQ ID NO: 5
84 <211> LENGTH: 7
85 <212> TYPE: PRT
86 <213> ORGANISM: Artificial Sequence
87 <220> FEATURE:
88 <223> OTHER INFORMATION: Modified human TGF alpha sequence fragment
89 <220> FEATURE:
90 <221> NAME/KEY: MISC_FEATURE
91 <222> LOCATION: (1)..(7)
92 <223> OTHER INFORMATION: Xaa at residue 1 and 4 is E or D; Xaa at residue 3 and
93         7 is V, G,
94         or A; Xaa at residue 5 is L or I; and Xaa at residue 6 is D or E
95 <400> SEQUENCE: 5
W--> 96         Xaa His Xaa Xaa Xaa Xaa Xaa
97         1              5
```

```
             RAW SEQUENCE LISTING                  DATE: 10/06/2004
             PATENT APPLICATION:  US/10/050,190    TIME: 15:48:33

             Input Set : N:\Crf3\RULE60\10050190.raw
             Output Set: N:\CRF4\10062004\J050190.raw
```

```
 99 <210> SEQ ID NO: 6
100 <211> LENGTH: 18
101 <212> TYPE: PRT
102 <213> ORGANISM: Artificial Sequence
103 <220> FEATURE:
104 <223> OTHER INFORMATION: Modified human TGF alpha sequence fragment
105 <220> FEATURE:
106 <221> NAME/KEY: MISC_FEATURE
107 <222> LOCATION: (1)..(18)
108 <223> OTHER INFORMATION: Xaa at residue 1, 5, 7-9, 14, 18 is indep. V, G, or A;
109       Xaa at
110       residue 6 is Y or F; Xaa at residue 10 is R or K; Xaa at residue 12,
111       15 is indep. E or D; Xaa at residue 16 is L or I; Xaa at residue
```
W--> 112   **17 is D or E**
```
113 <400> SEQUENCE: 6
```
W--> 114   **Xaa Cys His Ser Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa His Xaa Xaa Xaa**
```
115       1                   5                   10                  15
116       Xaa Xaa
118 <210> SEQ ID NO: 7
119 <211> LENGTH: 7
120 <212> TYPE: PRT
121 <213> ORGANISM: Artificial Sequence
122 <220> FEATURE:
123 <223> OTHER INFORMATION: Modified human TGF alpha sequence fragment
124 <220> FEATURE:
125 <221> NAME/KEY: MISC_FEATURE
126 <222> LOCATION: (1)..(7)
127 <223> OTHER INFORMATION: Xaa at residue 1 and 2 is indep. V, G, and A; Xaa at
128       residue 7 is
129       K or D
130 <400> SEQUENCE: 7
```
W--> 131   **Xaa Xaa Ser His Phe Asn Xaa**
```
132       1                   5
```

RAW SEQUENCE LISTING ERROR SUMMARY   DATE: 10/06/2004
PATENT APPLICATION: **US/10/050,190**   TIME: 15:48:34

    Input Set : **N:\Crf3\RULE60\10050190.raw**
    Output Set: **N:\CRF4\10062004\J050190.raw**

lease Note:

se of n and/or Xaa have been detected in the Sequence Listing. Please review the
equence Listing to ensure that a corresponding explanation is presented in the <220>
o <223> fields of each sequence which presents at least one n or Xaa.

eq#:4; Xaa Pos. 1,5,6,7,8,9,10
eq#:5; Xaa Pos. 1,3,4,5,6,7
eq#:6; Xaa Pos. 1,5,6,7,8,9,10,12,14,15,16,17,18
eq#:7; Xaa Pos. 1,2,7

nvalid Line Length:

he rules require that a line not exceed 72 characters in length. This includes spaces.

eq#:4; Line(s) 77
eq#:5; Line(s) 92
eq#:6; Line(s) 108

VERIFICATION SUMMARY
DATE: 10/06/2004
PATENT APPLICATION: **US/10/050,190**
TIME: 15:48:34

Input Set : **N:\Crf3\RULE60\10050190.raw**
Output Set: **N:\CRF4\10062004\J050190.raw**

```
79 M:258 W: Mandatory Feature missing, <220> Tag not found for SEQ ID#:4
80 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4 after pos.:0
96 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:0
112 M:259 W: Allowed number of lines exceeded, <223> Other Information:
114 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:0
341 Repeated in SeqNo=6
131 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:7 after pos.:0
```